Patents by Inventor David Rampe

David Rampe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7741493
    Abstract: The present invention relates to a novel series of 4,5-diphenyl-2-amino-4,5-dihydro-imidazole derivatives of the formula II: wherein R, R1, R2, R3, R4, R5, X and Y are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are P2X7 ion channel blockers and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases having an inflammatory component, including inflammatory bowel disease, rheumatoid arthritis and disease conditions associated with the central nervous system, such as stroke, Alzheimer's disease, etc.
    Type: Grant
    Filed: November 29, 2007
    Date of Patent: June 22, 2010
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Patrick Shum, Alexandre Gross, Liang Ma, Daniel G. McGarry, Gregory H. Merriman, David Rampe, Garth Ringheim, Jeffrey Stephen Sabol, Francis A. Volz
  • Patent number: 7534803
    Abstract: N-(Pyridinyl)-1H-indol-1-amines of formula I provide a unique combination of blocking properties for both the potassium and sodium channels. These compounds are useful for the treatment of Demyelinating Diseases and Conditions such as Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compounds are also useful for Stroke Rehabilitation, the treatment of Bladder Irritation and Dysfunction, and the treatment of Neuropathic Pain and Chemokine-Induced Pain.
    Type: Grant
    Filed: September 27, 2005
    Date of Patent: May 19, 2009
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Craig P. Smith, Michel P. Rathbone, Margaret Petty, David Rampe
  • Patent number: 7326792
    Abstract: The present invention relates to a novel series of 4,5-diphenyl-2-amino-4,5-dihydro-imidazole derivatives of the formula II: wherein R, R1, R2, R3, R4, R5, X and Y are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are P2X7 ion channel blockers and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases having an inflammatory component, including inflammatory bowel disease, rheumatoid arthritis and disease conditions associated with the central nervous system, such as stroke, Alzheimer's disease, etc.
    Type: Grant
    Filed: July 21, 2004
    Date of Patent: February 5, 2008
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Patrick Shum, Alexandre Gross, Liang Ma, Daniel G. McGarry, Gregory H. Merriman, David Rampe, Garth Ringheim, Jeffrey Stephen Sabol, Francis A. Volz
  • Patent number: 7230015
    Abstract: N-(Pyridinyl)-1H-indol-1-amines of formula I provide a unique combination of blocking properties for both the potassium and sodium channels. These compounds are useful for the treatment of Demyelinating Diseases and Conditions such as Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compounds are also useful for Stroke Rehabilitation, the treatment of Bladder Irritation and Dysfunction, and the treatment of Neuropathic Pain and Chemokine-Induced Pain.
    Type: Grant
    Filed: March 14, 2005
    Date of Patent: June 12, 2007
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Craig P Smith, Michel P Rathbone, Margaret Petty, David Rampe
  • Publication number: 20070129403
    Abstract: The present invention provides methods of treating schizophrenia and/or glucoregulatory abnormalities in a patient in need thereof comprising administering to said patient a therapeutically effective amount of a compound of formula I wherein in is 0, 1 or 2; n is 0, 1 or 2; p is 0 or 1; each R is independently hydrogen, halogen, trifluoromethyl, C1-C6alkyl, C1-C6alkoxy, benzyloxy, hydroxy, nitro or amino; each R1 is independently hydrogen, C1-C6alkyl, C1-C6alkenyl, C1-C6alkanoyl, halogen, cyano, —C(O)C1-C6alkyl, —C1-C6alkyleneCN, —C1-C6alkyleneNR?R? wherein R? and R? are each independently hydrogen or C1-C6alkyl, —C1-C6alkyleneOC(O)C1-C6alkyl, or —CH(OH)R4 wherein R4 is hydrogen or C1-C6alkyl; R2 is hydrogen, C1-C6alkyl optionally substituted with halogen, hydroxy or benlzyloxy, C1-C6alkenyl, C1-C6alkynyl, —CO2C1-C6alkyl, or —R5—NR?R? wherein R5 is C1-C6alkylene, C1-C6alkenylene or C1-C6alkynylene and R? and R? are each independently hydrogen, C1-C6alkyl or alternatively the group —NR?R? as a whole
    Type: Application
    Filed: September 29, 2006
    Publication date: June 7, 2007
    Applicant: AVENTIS PHARMACEUTICALS INC.
    Inventors: Craig Smith, David Rampe, Beth Borowsky, Sathapana Kongsamut
  • Patent number: 7179821
    Abstract: N-(Pyridinyl)-1H-indol-1-amines of formula I provide a unique combination of blocking properties for both the potassium and sodium channels. These compounds are useful for the treatment of Demyelinating Diseases and Conditions such as Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compounds are also useful for Stroke Rehabilitation, the treatment of Bladder Irritation and Dysfunction, and the treatment of Neuropathic Pain and Chemokine-Induced Pain.
    Type: Grant
    Filed: March 14, 2005
    Date of Patent: February 20, 2007
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Craig P Smith, Michel P Rathbone, Margaret Petty, David Rampe
  • Publication number: 20060025452
    Abstract: N-(Pyridinyl)-1H-indol-1-amines of formula I provide a unique combination of blocking properties for both the potassium and sodium channels. These compounds are useful for the treatment of Demyelinating Diseases and Conditions such as Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compounds are also useful for Stroke Rehabilitation, the treatment of Bladder Irritation and Dysfunction, and the treatment of Neuropathic Pain and Chemokine-Induced Pain.
    Type: Application
    Filed: September 27, 2005
    Publication date: February 2, 2006
    Applicant: Avenits Pharmaceuticals Inc.
    Inventors: Craig Smith, Michel Rathbone, Margaret Petty, David Rampe
  • Patent number: 6967210
    Abstract: N-(Pyridinyl)-1H-indol-1-amines of formula I provide a unique combination of blocking properties for both the potassium and sodium channels. These compounds are useful for the treatment of Demyelinating Diseases and Conditions such as Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compounds are also useful for Stroke Rehabilitation, the treatment of Bladder Irritation and Dysfunction, and the treatment of Neuropathic Pain and Chemokine-Induced Pain.
    Type: Grant
    Filed: February 14, 2002
    Date of Patent: November 22, 2005
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Craig P. Smith, Michel P. Rathbone, Margaret Petty, David Rampe
  • Publication number: 20050234105
    Abstract: N-(Pyridinyl)-1H-indol-1-amines of formula I provide a unique combination of blocking properties for both the potassium and sodium channels. These compounds are useful for the treatment of Demyelinating Diseases and Conditions such as Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compounds are also useful for Stroke Rehabilitation, the treatment of Bladder Irritation and Dysfunction, and the treatment of Neuropathic Pain and Chemokine-Induced Pain.
    Type: Application
    Filed: March 14, 2005
    Publication date: October 20, 2005
    Applicant: Aventis Pharmaceuticals Inc.
    Inventors: Craig Smith, Michel Rathbone, Margaret Petty, David Rampe
  • Publication number: 20050159456
    Abstract: N-(Pyridinyl)-1H-indol-1-amines of formula I provide a unique combination of blocking properties for both the potassium and sodium channels. These compounds are useful for the treatment of Demyelinating Diseases and Conditions such as Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compounds are also useful for Stroke Rehabilitation, the treatment of Bladder Irritation and Dysfunction, and the treatment of Neuropathic Pain and Chemokine-Induced Pain.
    Type: Application
    Filed: March 14, 2005
    Publication date: July 21, 2005
    Applicant: Aventis Pharmaceuticals Inc.
    Inventors: Craig Smith, Michel Rathbone, Margaret Petty, David Rampe
  • Publication number: 20050026916
    Abstract: The present invention relates to a novel series of 4,5-diphenyl-2-amino-4,5-dihydro-imidazole derivatives of the formula II: wherein R, R1, R2, R3, R4, R5, X and Y are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are P2X7 ion channel blockers and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases having an inflammatory component, including inflammatory bowel disease, rheumatoid arthritis and disease conditions associated with the central nervous system, such as stroke, Alzheimer's disease, etc.
    Type: Application
    Filed: July 21, 2004
    Publication date: February 3, 2005
    Applicant: Aventis Pharmaceuticals Inc.
    Inventors: Patrick Shum, Alexandre Gross, Liang Ma, Daniel McGarry, Gregory Merriman, David Rampe, Garth Ringheim, Jeffrey Sabol, Francis Volz
  • Publication number: 20040157888
    Abstract: N-(Pyridinyl)-1H-indol-1-amines of formula I provide a unique combination of blocking properties for both the potassium and sodium channels. These compounds are useful for the treatment of Demyelinating Diseases and Conditions such as Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compounds are also useful for Stroke Rehabilitation, the treatment of Bladder Irritation and Dysfunction, and the treatment of Neuropathic Pain and Chemokine-Induced Pain.
    Type: Application
    Filed: February 3, 2004
    Publication date: August 12, 2004
    Applicant: Aventis Pharmaceuticals Inc.
    Inventors: Craig P. Smith, Michel P. Rathbone, Margaret Petty, David Rampe
  • Publication number: 20040157889
    Abstract: N-(Pyridinyl)-1H-indol-1-amines of formula I provide a unique combination of blocking properties for both the potassium and sodium channels. These compounds are useful for the treatment of Demyelinating Diseases and Conditions such as Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compounds are also useful for Stroke Rehabilitation, the treatment of Bladder Irritation and Dysfunction, and the treatment of Neuropathic Pain and Chemokine-Induced Pain.
    Type: Application
    Filed: February 3, 2004
    Publication date: August 12, 2004
    Applicant: Aventis Pharmaceuticals Inc.
    Inventors: Craig P. Smith, Michel P. Rathbone, Margaret Petty, David Rampe
  • Publication number: 20030105150
    Abstract: N-(Pyridinyl)-1H-indol-1-amines of formula I provide a unique combination of blocking properties for both the potassium and sodium channels. These compounds are useful for the treatment of Demyelinating Diseases and Conditions such as Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compounds are also useful for Stroke Rehabilitation, the treatment of Bladder Irritation and Dysfunction, and the treatment of Neuropathic Pain and Chemokine-Induced Pain.
    Type: Application
    Filed: February 14, 2002
    Publication date: June 5, 2003
    Inventors: Craig P. Smith, Michel P. Rathbone, Margaret Petty, David Rampe